EPS for Mediwound Ltd (MDWD) Expected At $-0.19; 1PM INDUSTRIES (OPMZ) SI Increased By 400%

July 17, 2017 - By Adrian Erickson

Analysts expect Mediwound Ltd (NASDAQ:MDWD) to report $-0.19 EPS on July, 27.They anticipate $0.15 EPS change or 44.12% from last quarter’s $-0.34 EPS. After having $-0.20 EPS previously, Mediwound Ltd’s analysts see -5.00% EPS growth. It closed at $7.05 lastly. It is down 11.84% since July 17, 2016 and is downtrending. It has underperformed by 28.54% the S&P500.

1PM INDUSTRIES INCORPORATED (OTCMKTS:OPMZ) had an increase of 400% in short interest. OPMZ’s SI was 500 shares in July as released by FINRA. Its up 400% from 100 shares previously. It closed at $0.0008 lastly. It is down 0.00% since July 17, 2016 and is . It has underperformed by 16.70% the S&P500.

1pm Industries, Inc., formerly Torrent Energy Corp., is focused on the sale and distribution of medical marijuana under the brand Von Baron Farms. The company has market cap of $490,700. The Firm sells various products, including Cookie Spread, Peanut Butter, CBD Cookie Spread, CBD Mango Shot, THC Shot, Combo Shot, and Pancake and Waffle Batter. It has a 0.05 P/E ratio. The Firm distributes its Von Baron Farms product at www.vonbaronfarms.com.

Among 6 analysts covering MediWound (NASDAQ:MDWD), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. MediWound had 8 analyst reports since August 10, 2015 according to SRatingsIntel. The stock has “Buy” rating by SunTrust on Wednesday, March 23. As per Monday, August 10, the company rating was reinitiated by Credit Suisse. The firm has “Outperform” rating by Wells Fargo given on Wednesday, August 17. The firm has “Buy” rating by Oppenheimer given on Tuesday, June 27. The stock of Mediwound Ltd (NASDAQ:MDWD) earned “Buy” rating by Jefferies on Monday, June 12.

MediWound Ltd. is a biopharmaceutical company. The company has market cap of $160.47 million. The Firm focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. It currently has negative earnings. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>